ஜெஃப் ஆல்பர்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Blueprint Medicines Reports Second Quarter 2021 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
FDA Expands Approval of Blueprint Medicines Ayvakit to Include Rare Blood Disorder
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
FDA Approves Blueprint Medicines AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced systemic mastocytosis Announced a potential best-in-class research program targeting CDK2 for the treatment of multiple cancers with tumor-associated cell cycle defects Plan to provide updates across multiple clinical and research programs at AACR 2021 Annual Meeting Ended 2020 with approximately $1.5 billion in cash
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.